原发性肝癌术前放疗及免疫治疗的研究进展

Research progress in the preoperative radiotherapy and immunotherapy for primary liver cancer

我国是肝癌大国,近年来肝癌治疗方式越来越趋于综合性的治疗,主要包括手术、消融、介入栓塞、放疗、化疗、靶向、免疫、肝移植等治疗。目前,肝癌手术切除率低是影响预后主要因素之一,肝癌术前新辅助治疗或转化治疗可以最大程度的提高手术切除率,改善预后。随着放疗和免疫治疗在肝癌综合治疗中的快速发展,肝癌术前放疗及免疫独特的治疗效果逐渐被证实改善患者预后。故本文通过搜索国内外相关文献报道,综述了肝癌术前放疗及免疫治疗的研究进展。

Liver cancer is one of the most common cancers in China.In recent years,liver cancer tends to be treated with comprehensive therapies,including surgery,ablation,interventional embolization,radiotherapy,chemotherapy,targeted therapy,immunotherapy,and liver transplantation.At present,the low surgical resectionrate is one of the main factors affecting the prognosis of liver cancer patients.Preoperative neoadjuvant therapy or conversion therapy for liver cancer can maximize the rate of surgical resection and improve the prognosis.With the rapid development of radiotherapy and immunotherapy in the comprehensive treatment of liver cancer,it has been gradually confirmed that the unique effects of preoperative radiotherapy and immune therapy for liver cancer can improve the prognosis of the patients.Therefore,this paper reviewed the research progress in the preoperative radiotherapy and immunotherapy for liver cancer by searching relevant literature and reports at home and abroad.